Sr. HEOR Evidence Generation Manager at Bristol-Myers Squibb

Shanghai, China

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

PharmaceuticalsIndustries

Requirements

Master’s degree in health economics, health administration, public health, or related disciplines
6+ years of experience in pharmaceutical/healthcare companies or consulting firms, with hands-on experience in HEOR evidence generation, modeling, and data analysis
Solid technical expertise in health economics and outcomes research
Proven ability to execute evidence generation projects independently
Strong communication and teamwork skills
Fluency in English, both verbally and in writing
Willingness to travel up to 30%, mostly domestic

Responsibilities

Design, implement, and execute evidence generation activities according to HEOR strategies and business priorities
Collaborate with global and local cross-functional teams to deliver robust health economic analyses and outcomes research for pipeline and in-market products
Conduct modeling, data analysis, and comparative effectiveness studies (CEA, BIA, systematic reviews/meta-analyses) for access, pricing, and value proposition
Prepare health economics sections for value dossiers and submission materials to support market access and reimbursement objectives
Assist with internal HEOR trainings, share best practices, and support capability-building initiatives
Maintain high-quality and timely delivery of health economics evidence, ensuring alignment with strategic needs and regulatory requirements
Participate in and contribute to relevant HEOR conferences, including assisting with dissemination of research outputs at scientific forums and journals
Perform any other duties as assigned

Skills

HEOR

Health Economics

Outcomes Research

CEA

BIA

Systematic Reviews

Meta-Analyses

Economic Modeling

Data Analysis

Value Dossiers

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free